Approved medicines Human randomized trial Metabolic health
Also discussed as: Ozempic, Wegovy, Rybelsus
What it is and how it works
Semaglutide activates GLP-1 receptors involved in glucose regulation and appetite signaling. A mechanism describes what a molecule does biologically; the clinical trial is what tests whether that activity changes a meaningful outcome in a defined group of people.
Source for the mechanism context →A closer look at the cited evidence
Human randomized trial
This label describes the selected source below. It is not a complete ranking of the literature, a safety score, or an approval status.
- Study or assessment
- Wilding et al., 2021 — STEP 1 randomized trial
- Design
- Randomized, double-blind, placebo-controlled trial; 68 weeks.
- Who or what was studied
- 1,961 adults with overweight or obesity, without diabetes; both groups received lifestyle intervention.
- What was observed
- The semaglutide group had a greater average reduction in body weight than the placebo group.
- Limits of interpretation
- This selected trial does not predict an individual result, cover every semaglutide formulation, or establish a general longevity benefit.
What the evidence means
Clinical evidence supports specific approved uses; findings depend on the product, population, and indication.
Approval and regulatory context
Some products have FDA-approved diabetes or weight-management indications. Approval does not extend to every formulation or online product.
Safety and uncertainty
Side effects, contraindications, interactions, and monitoring depend on the prescribed product. Unapproved versions raise additional quality concerns.
What remains uncertain
Claims about an unapproved product require separate scrutiny of identity, formulation, and quality. A familiar ingredient name cannot establish equivalence to the medicine studied. Medical suitability remains an individual clinical assessment.
These summaries are introductory and are not a complete account of the literature, adverse effects, contraindications, or interactions. Absence of a listed risk does not mean absence of risk. Different compounds, formulations, and routes cannot be treated as interchangeable.
Sources behind this overview
- NIH / NIDDK: prescription medicines and weight management
- FDA: concerns about unapproved GLP-1 products
- Wilding et al., 2021 — STEP 1 randomized trial
- DailyMed — Wegovy mechanism and safety
Read the source in its full context. Source links support the overview; they do not imply endorsement of this library by the source organization.